GR-MD-02
Sponsors
Galectin Therapeutics Inc., Providence Health & Services
Conditions
Head and Neck Squamous Cell CarcinomaHypertension, PortalMelanomaMetastatic MelanomaNon-Alcoholic Steatohepatitis (NASH)Non-Small Cell Lung CancerNonalcoholic SteatohepatitisPsoriasis
Phase 1
Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis
CompletedNCT01899859
Start: 2013-07-31End: 2015-02-28Updated: 2015-02-23
GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients
CompletedNCT02575404
Start: 2016-05-16End: 2022-10-10Updated: 2023-06-05
Phase 2
An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis
CompletedNCT02407041
Start: 2015-09-30End: 2018-03-31Updated: 2020-09-07
Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis
CompletedNCT02421094
Start: 2015-09-30End: 2016-09-27Updated: 2020-10-08
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
CompletedNCT02462967
Start: 2015-06-30End: 2017-10-31Updated: 2020-10-08
GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients
WithdrawnNCT04987996
Start: 2023-07-01End: 2031-07-01Updated: 2023-06-06